MeiraGTx (MGTX) vs Savara (SVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Savara (SVRA) has outperformed MeiraGTx (MGTX) over the past year, gaining 39.2% versus a gain of 27.1%. Over five years, SVRA leads with a +274.4% price change compared with -26.5% for MGTX. MeiraGTx is the larger company by market cap ($1.01 billion vs $992.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MGTX | SVRA |
|---|---|---|
| Share price | $10.50 | $4.83 |
| Market cap | $1.01B | $992.37M |
| 1-day change | -2.96% | -1.02% |
| YTD return | +32.08% | -19.90% |
| 1-year return | +27.12% | +39.19% |
| 5-year return | -26.47% | +274.42% |
| P/E ratio (TTM) | 12.07 | — |
| EPS (TTM) | $0.87 | $-0.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.35 | $7.01 |
| 52-week low | $6.62 | $3.35 |
| Distance from 52-week high | -31.60% | -31.05% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +164.29% | +128.99% |
| Average volume | 792.38K | 1.83M |
| Shares outstanding | 96.04M | 205.46M |
| Employees | 393 | 70 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SVRA has outperformed MGTX by 12.1 percentage points over the past year.
About MeiraGTx
MGTX stock →MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 393 employees
About Savara
SVRA stock →Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 70 employees
MGTX vs SVRA FAQ
Which is bigger, MeiraGTx or Savara?
MeiraGTx (MGTX) is larger, with a market capitalization of $1.01B compared with $992.37M for Savara (SVRA).
Which stock has performed better over the past year, MGTX or SVRA?
SVRA returned +39.19% over the past 12 months, compared with +27.12% for MGTX (price return, excluding dividends). Past performance does not predict future results.
Are MeiraGTx and Savara in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for MeiraGTx and Biotechnology: Pharmaceutical Preparations for Savara.